IP Library Granted Patent US 11,459,623
Granted Patent B2
US 11,459,623 · App. 16/611,000 · Granted Oct 4, 2022

In vitro method for detecting and quantifying HIV-2 DNA

Inventors: Adeline Melard (Morangis, FR); Mélanie Bertine (Bretigny sur Orge, FR); Véronique Avettand Fenoel (Paris, FR); Florence Damond (Saint Mande, FR); Christine Rouzioux (Paris, FR); Diane Descamps (Paris, FR); Marie Gueudin (Rouen, FR); Jean-Christophe Plantier (Bois-Guillaume, FR)
Assignees: UNIVERSITÉ PARIS CITÉ; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS; CHU DE ROUEN; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; UNIVERSITE DE ROUEN; UNIVERSITÉ PARIS NORD
C12Q1/703C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,459,623
App. No.
16/611,000
Granted
Oct 4, 2022
Kind
B2
Abstract

The present invention relates to a method for detecting or quantifying deoxyribonucleic acid (DNA) of human immunodeficiency virus 2 (HIV-2) in a sample containing DNA comprising: a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, with at least two sets of primers and probe each respectively comprising two primers and a labeled probe for the detection or quantification of HIV-2 DNA, at least one of the sets is selected from the group consisting of: a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having al least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identify to SEQ ID NO: 3 or the complement of these sequences, and a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 4 or a sequence having at least 90% identity to SEQ ID NO: 4, a primer comprising or consisting of a sequence SEQ ID NO: 5 or a sequence having 90% identity to SEQ ID NO: 5 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 6 or a sequence having at least 90% identity to SEQ ID NO: 6 or the complement of these sequences, and b) determining therefrom the presence or absence and/or the quantity of HIV-2 DNA in the biological sample.

Claims (44)

1. A method for detecting or quantifying deoxyribonucleic acid (DNA) of human immunodeficiency virus 2 (HIV-2) in a sample containing DNA comprising:

a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, with at least two sets of primers and probe each respectively comprising two primers and a labeled probe for the detection or quantification of HIV-2 DNA, at least one of the sets being selected from the group consisting of:

a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complement of these sequences, and

a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 4 or a sequence having at least 90% identity to SEQ ID NO: 4, a primer comprising or consisting of a sequence SEQ ID NO: 5 or a sequence having 90% identity to SEQ ID NO: 5 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 6, or a sequence having at least 90% identity to SEQ ID NO: 6 or the complement of these sequences, and

b) determining therefrom the presence or absence and/or the quantity of HIV-2 DNA in the biological sample,

wherein the primers and probes are each present at a concentration between 300 and 500 nM.

2. The method according to claim 1 , wherein in step

a) of performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, is performed with:

(i) at least 4 primers respectively comprising or consisting of:

a sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO: 1 or the complement of these sequences, and

a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and

a sequence SEQ ID NO: 4 or a sequence having 90% identity to SEQ ID NO: 4 or the complement of these sequences, and

a sequence SEQ ID NO: 5 or a sequence having 90% identity to SEQ ID NO: 5 or the complement of these sequences, and

(ii) at least 2 labelled probes respectively comprising or consisting of:

a sequence SEQ ID NO: 3, a sequence complement to SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complement thereof, and

a sequence SEQ ID NO: 6, a sequence complement to SEQ ID NO: 6, or a sequence having at least 90% identity to SEQ ID NO: 6 or the complement thereof.

3. The method according to claim 1 , wherein the sample containing DNA is a biological sample or a sample comprising cells infected in vitro by HIV-2.

4. The method according to claim 1 , wherein the primers respectively consist of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 5, and the labeled probes respectively consist of sequences SEQ ID NO: 3 and SEQ ID NO: 6.

5. The method according to claim 1 , wherein the labelled probes are labelled with 6-carboxyfluorescein (FAM) at their 5′end and with Black Hole Quencher-1 (BHQ1) at their 3′ end.

6. The method according to claim 1 , wherein at least one DNA virus or at least one DNA molecule having essentially no sequence similarity with the genomic sequence of HIV-2 is added to the sample or the fraction thereof, as well as primers and probe necessary for its amplification and detection by real-time PCR, as an internal control of extraction and/or inhibition.

7. The method according to claim 1 , wherein the PCR comprises the following thermocycling conditions:

2 min at 50° C., followed by

10 min at 95° C., followed by

50 cycles of 95° C. for 15 s and 60° C. for 1 min.

8. The method according to claim 1 , further comprising determining or quantifying HIV-1 nucleic acids in the sample or a fraction thereof.

9. A kit or a mix for detecting or quantifying HIV-2 DNA, comprising:

a) at least two sets of primers and probe each respectively comprising two primers and one probe for the detection or quantification of HIV-2 DNA, the primers and probe being each present at a concentration between 300 and 500 nM, and at least one of the sets being selected from the group consisting of:

a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or the complement of these sequences, and a labelled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complement of these sequences, and

a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 4 or a sequence having at least 90% identity with SEQ ID NO: 4, a primer comprising or consisting of a sequence SEQ ID NO: 5 or a sequence having 90% identity to SEQ ID NO: 5 or the complement of these primers, and a labelled probe comprising or consisting of a sequence SEQ ID NO: 6, or a sequence having at least 90% identity to SEQ ID NO: 6 or the complement of these sequences, and

b) at least one DNA virus or at least one DNA molecule having essentially no sequence similarity with the genomic sequence of HIV-2, as well as primers and probe necessary for its amplification and detection by real-time PCR, as an internal control of extraction and/or inhibition, and

c) optionally additional reagents for performing a PCR.

10. The kit or the mix according to claim 9 , comprising:

a1) at least 4 primers, at a concentration between 300 and 500 nm, respectively comprising or consisting of:

a sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO: 1 or the complement of these sequences, and

a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and

a sequence SEQ ID NO: 4 or a sequence having 90% identity to SEQ ID NO: 4 or the complement of these sequences, and

a sequence SEQ ID NO: 5 or a sequence having 90% identity to SEQ ID NO: 5 or the complement of these sequences, and

a2) at least 2 labelled probes at a concentration between 300 and 500 nM, respectively comprising or consisting of:

a sequence SEQ ID NO: 3, a sequence complement to SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complement thereof, and

a sequence SEQ ID NO: 6, a sequence complement to SEQ ID NO: 6, or a sequence having at least 90% identity to SEQ ID NO: 6 or the complement thereof.

11. The kit or the mix according to claim 9 , further comprising primers and at least one labelled probe for detecting or quantifying HIV-1 nucleic acids.

12. An in vitro method for determining HIV-2 viral load, in an individual, comprising the steps of:

(c) performing the method for detecting or quantifying HIV-2 DNA in a biological sample taken from the individual as defined in claim 1 ; and

(d) determining therefrom the HIV-2 viral load of the individual.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE EFFECTIVE DATE OF THE NUNC PRO TUNC PREVIOUSLY RECORDED AT REEL: 060883 FRAME: 0855. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC . Recorded Aug 30, 2022
From: MELARD, ADELINE; AVETTAND FENOEL, VERONIQUE; DAMOND, FLORENCE; ROUZIOUX, CHRISTINE; DESCAMPS, DIANE; GUEDIN, MARIE; PLANTIER, JEAN-CHRISTOPHE
To: UNIVERSITE PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS; UNIVERSITE PARIS DIDEROT; UNIVERSITE PARIS NORD; UNIVERSITE DE ROUEN; CHU DE ROUEN
Reel/Frame 061355/0754 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NUNC PRO TUNC EFFECTIVE DATE PREVIOUSLY RECORDED AT REEL: 060896 FRAME: 0068. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Aug 30, 2022
From: BERTINE, MELANIE
To: UNIVERSITE PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS; UNIVERSITE PARIS DIDEROT; UNIVERSITE PARIS NORD; UNIVERSITE DE ROUEN; CHU DE ROUEN
Reel/Frame 061356/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2022
From: BERTINE, MÉLANIE
To: UNIVERSITE PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS; UNIVERSITE PARIS DIDEROT; UNIVERSITE PARIS NORD; UNIVERSITE DE ROUEN; CHU DE ROUEN
Reel/Frame 060896/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2022
From: MELARD, ADELINE; FENOEL, VÉRONIQUE AVETTAND; DAMOND, FLORENCE; ROUZIOUX, CHRISTINE; DESCAMPS, DIANE; GUEUDIN, MARIE; PLANTIER, JEAN-CHRISTOPHE
To: UNIVERSITE PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS; UNIVERSITE PARIS DIDEROT; UNIVERSITE PARIS NORD; UNIVERSITE DE ROUEN; CHU DE ROUEN
Reel/Frame 060883/0855 →
CHANGE OF NAME Recorded Mar 25, 2022
From: UNIVERSITÉ DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059504/0225 →
MERGER Recorded Aug 17, 2021
From: UNIVERSITE DE PARIS DESCARTES; UNIVERSITE PARIS DIDEROT - PARIS 7
To: UNIVERSITE DE PARIS
Reel/Frame 057197/0254 →